Search All News
CancerFIT—a free exercise program at CUIMC for cancer patients and survivors—offers more than a physical workout, it also provides much-needed support and inspiration.
Columbia biomedical engineers have designed a bacteria strain that seeks out solid tumors and safely delivers immunotherapies, resulting in tumor regression in mouse models.
The three scientists honored by the 2019 Horwitz Prize played key roles in identifying and deciphering the PI3K pathway, which has led to new treatments for several types of cancer.
By learning how contagious cancer spreads among shellfish, scientists hope to better understand how cancer metastasizes in people.
- March 28, 2017
Based on new evidence, laparoscopic surgery should be offered to most women with early-stage endometrial cancer, says Columbia’s gynecologic cancer chief.
- March 27, 2017
A public-private research effort aims to develop more accurate ways of tracking a patient’s response to cancer therapy.
- March 7, 2017
The drug, developed by Columbia and MSK researchers, selectively kills cancer cells and has shown activity against multiple malignancies in pre-clinical studies.
- February 27, 2017
Bristol-Myers Squibb Company today announced that Columbia University Medical Center and Peter MacCallum Cancer Centre have joined the International Immuno-Oncology Network.
- February 14, 2017
In her JAMA editorial, Columbia oncologist Dawn Hershman says clinical trials show cooling caps reduce hair loss in some women undergoing chemotherapy.
- January 12, 2017
Collaboration will investigate a system biology approach to identifying treatment options for patients with advanced gastrointestinal stromal tumors (GIST).
- December 22, 2016
Columbia University researchers have created a user-friendly program that rapidly predicts which genes are implicated in an individual’s cancer and recommends treatments.
- December 16, 2016
Researchers have found that blocking nerve growth factor inhibits the formation of stomach cancers, according to a study in mice.
- December 5, 2016
In a phase 1 study, eight out of 12 patients with relapsed and/or refractory blood cancers responded to a combination of two common chemotherapy drugs.